Skip to main content
Premium Trial:

Request an Annual Quote

NHGRI Grants Support for 'Revolutionary' Sequencing for $1,000 Genome

NEW YORK (GenomeWeb News) – The National Human Genome Research Institute plans to support a number of researchers under four grant programs focused on developing transformative technologies and methods that can help to bring the cost of sequencing a mammalian-sized genome down to around $1,000 by around the year 2014.
 
The “Revolutionary Genome Sequencing Technologies” grant program will support high-risk, high-reward research that aims to develop full-scale sequencing systems or to investigate underlying system components or methods different than those currently being pursued. The grants continue funding for the program, which began in 2004.
 
Under one program, NHGRI may grant as much as $5 million in fiscal 2009 to between two and seven awardees. Applicants for these funds may seek up to $1.5 million per year for a period of up to five years. 
 
A parallel grant program would give up to $2 million over three years to between two and seven grantees, for direct costs of up to $200,000 per year.
 
A Small Business Innovation Research Grant from NHGRI will grant between four and six small businesses up to a total of $3.6 million in fiscal 2009 to propose novel technologies to bring down the cost of sequencing. Phase I of this program will give up to $250,000 of total costs per year for up to two years, and Phase II applicants may seek up to $1.5 million total costs per year for up to three years.
 
A parallel Small Business Technology Transfer program will spend up to $2 million in fiscal 2009 to support between two and five awards to small businesses investigating the development of new sequencing methods. This program will award up to $250,000 total costs per year for up to two years for Phase I programs, and it will support up to $1.5 million in total costs per year for up to three years for Phase II programs.
 

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.